GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Change In Receivables

Bionik Laboratories (Bionik Laboratories) Change In Receivables : $-0.18 Mil (TTM As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Change In Receivables?

Bionik Laboratories's change in receivables for the quarter that ended in Mar. 2023 was $-0.12 Mil. It means Bionik Laboratories's Accounts Receivable increased by $0.12 Mil from Dec. 2022 to Mar. 2023 .

Bionik Laboratories's change in receivables for the fiscal year that ended in Mar. 2023 was $-0.18 Mil. It means Bionik Laboratories's Accounts Receivable increased by $0.18 Mil from Mar. 2022 to Mar. 2023 .

Bionik Laboratories's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.45 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Bionik Laboratories's Days Sales Outstanding for the three months ended in Mar. 2023 was 82.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bionik Laboratories's liquidation value for the three months ended in Mar. 2023 was $-3.72 Mil.


Bionik Laboratories Change In Receivables Historical Data

The historical data trend for Bionik Laboratories's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Change In Receivables Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 0.51 0.41 0.18 -0.18

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 0.16 -0.46 0.24 -0.12

Bionik Laboratories Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionik Laboratories  (OTCPK:BNKL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Bionik Laboratories's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.453/0.501*91
=82.51

2. In Ben Graham's calculation of liquidation value, Bionik Laboratories's accounts receivable are only considered to be worth 75% of book value:

Bionik Laboratories's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.427-5.003+0.75 * 0.453+0.5 * 1.034
=-3.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionik Laboratories Change In Receivables Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291